The European Medicines Agency’s, EMA, committee recommended a change to extend the use of Eli Lilly’s (LLY) Mounjaro for the treatment of type 2 diabetes, that is not satisfactorily controlled, to adolescents and children from 10 years of age, together with diet and physical activity. In adults, Mounjaro is also used to treat type 2 diabetes and to help individuals with obesity or who are overweight and who have weight-related health problems lose weight and keep their weight under control.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly’s New Study on LY3549492: A Potential Breakthrough in Obesity Treatment
- Eli Lilly’s New Study on LY4213663: A Potential Game-Changer for Rheumatoid Arthritis?
- Eli Lilly’s New Study on LY4584180: A Potential Game-Changer in Blood Cancer Treatment?
- Eli Lilly’s New Study on Obesity Drug LY4167586: What Investors Need to Know
- Eli Lilly’s Orforglipron Study: A Potential Game-Changer for PAD Treatment